our mission is to develop disease-modifying therapeutics for patients suffering from neurological disorders such as huntington’s disease and alzheimer’s disease by targeting complement-mediated neurodegeneration (cmnd).
Company profile
Ticker
ANNX
Exchange
Website
CEO
Douglas Love
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Annexon Biosciences Australia Pty Ltd ...
IRS number
275414423
ANNX stock data
Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
5 Apr 24
EFFECT
Notice of effectiveness
2 Apr 24
S-3
Shelf registration
26 Mar 24
S-8
Registration of securities for employees
26 Mar 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
26 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K/A
Entry into a Material Definitive Agreement
22 Dec 23
8-K
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
21 Dec 23
Latest ownership filings
SC 13G
BB BIOTECH AG
22 Apr 24
4
William H. Carson
10 Apr 24
4
Douglas Love
21 Feb 24
4
Jamie Dananberg
21 Feb 24
4
DEAN RICHARD ARTIS
21 Feb 24
4
Jennifer Lew
21 Feb 24
4
Ted Yednock
21 Feb 24
4
Michael Overdorf
21 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 134.19 mm | 134.19 mm | 134.19 mm | 134.19 mm | 134.19 mm | 134.19 mm |
Cash burn (monthly) | (no burn) | 6.46 mm | 11.59 mm | 12.53 mm | 9.43 mm | 10.40 mm |
Cash used (since last report) | n/a | 44.23 mm | 79.41 mm | 85.85 mm | 64.59 mm | 71.23 mm |
Cash remaining | n/a | 89.96 mm | 54.78 mm | 48.34 mm | 69.60 mm | 62.96 mm |
Runway (months of cash) | n/a | 13.9 | 4.7 | 3.9 | 7.4 | 6.1 |
Institutional ownership, Q2 2023
94.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 102 |
Opened positions | 27 |
Closed positions | 31 |
Increased positions | 38 |
Reduced positions | 18 |
13F shares | Current |
---|---|
Total value | 184.46 bn |
Total shares | 73.92 mm |
Total puts | 151.70 k |
Total calls | 505.80 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Satter Management | 7.06 mm | $24.84 bn |
Bain Capital Life Sciences Investors | 5.70 mm | $20.07 bn |
Venrock Healthcare Capital Partners II | 4.93 mm | $0.00 |
Biotechnology Value Fund L P | 3.78 mm | $0.00 |
Redmile | 3.50 mm | $12.33 bn |
Logos Global Management | 3.50 mm | $12.32 bn |
BLK Blackrock | 3.48 mm | $12.25 bn |
FHI Federated Hermes Inc - Ordinary Shares | 3.06 mm | $10.76 bn |
Bain Capital Life Sciences Fund | 2.94 mm | $6.18 mm |
New Enterprise Associates 15 | 2.50 mm | $62.47 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 24 | William H. Carson | Common Stock | Buy | Acquire P | No | Yes | 6.066 | 3,200 | 19.41 k | 3,200 |
12 Feb 24 | Ted Yednock | Common Stock | Sell | Dispose S | No | No | 5.54 | 1,810 | 10.03 k | 36,075 |
12 Feb 24 | Lew Jennifer | Common Stock | Sell | Dispose S | No | No | 5.54 | 1,809 | 10.02 k | 45,651 |
12 Feb 24 | Douglas Love | Common Stock | Sell | Dispose S | No | No | 5.54 | 5,782 | 32.03 k | 196,121 |
12 Feb 24 | Michael Overdorf | Common Stock | Sell | Dispose S | No | No | 5.53 | 1,349 | 7.46 k | 48,592 |
News
Cantor Fitzgerald Reiterates Overweight on Annexon
24 Apr 24
Needham Reiterates Buy on Annexon, Maintains $16 Price Target
11 Apr 24
10 Health Care Stocks With Whale Alerts In Today's Session
9 Apr 24
Cantor Fitzgerald Reiterates Overweight on Annexon
3 Apr 24
Wells Fargo Maintains Overweight on Annexon, Maintains $12 Price Target
1 Apr 24
Press releases
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
16 Apr 24
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
26 Mar 24
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
18 Mar 24
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic Approach
21 Feb 24